Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated.In this open-label, parallel-group treat-to-target trial, participants were...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5070831?pdf=render |
id |
doaj-e1e792590f064a49b1f0a639e0f52050 |
---|---|
record_format |
Article |
spelling |
doaj-e1e792590f064a49b1f0a639e0f520502020-11-25T01:45:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016335010.1371/journal.pone.0163350Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.Ajay KumarEdward FranekJonathan WiseMarcus NiemeyerHenriette MersebachRafael SimóThe efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated.In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or IGlar OD (as per label, n = 264). Participants then entered a 26-week extension phase (IDegAsp OD, n = 192; IGlar OD, n = 221). The primary endpoint was change from baseline to Week 26 in HbA1c.After 26 and 52 weeks, mean HbA1c decreased to similar levels in both groups. After 52 weeks, the mean estimated treatment difference was -0.08% (-0.26, 0.09 95%CI), confirming the non-inferiority of IDegAsp OD versus IGlar OD evaluated at Week 26. After 52 weeks, there was a similar reduction in mean fasting plasma glucose in both treatment groups. The rate of confirmed hypoglycemic episodes was 86% higher (p < 0.0001) whereas the rate of nocturnal hypoglycemia was 75% lower (p < 0.0001) for IDegAsp versus IGlar.Nocturnal-confirmed hypoglycemia was higher with IGlar whereas overall and diurnal hypoglycemia were higher with IDegAsp dosed at breakfast. These results highlight the importance of administration of IDegAsp with the main meal of the day, tailored to the individual patient's needs.ClinicalTrials.gov: NCT01045707 [core]) and NCT01169766 [ext].http://europepmc.org/articles/PMC5070831?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ajay Kumar Edward Franek Jonathan Wise Marcus Niemeyer Henriette Mersebach Rafael Simó |
spellingShingle |
Ajay Kumar Edward Franek Jonathan Wise Marcus Niemeyer Henriette Mersebach Rafael Simó Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLoS ONE |
author_facet |
Ajay Kumar Edward Franek Jonathan Wise Marcus Niemeyer Henriette Mersebach Rafael Simó |
author_sort |
Ajay Kumar |
title |
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. |
title_short |
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. |
title_full |
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. |
title_fullStr |
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. |
title_full_unstemmed |
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. |
title_sort |
efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (u100) for 52 weeks in insulin-naïve patients with type 2 diabetes: a randomized controlled trial. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated.In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or IGlar OD (as per label, n = 264). Participants then entered a 26-week extension phase (IDegAsp OD, n = 192; IGlar OD, n = 221). The primary endpoint was change from baseline to Week 26 in HbA1c.After 26 and 52 weeks, mean HbA1c decreased to similar levels in both groups. After 52 weeks, the mean estimated treatment difference was -0.08% (-0.26, 0.09 95%CI), confirming the non-inferiority of IDegAsp OD versus IGlar OD evaluated at Week 26. After 52 weeks, there was a similar reduction in mean fasting plasma glucose in both treatment groups. The rate of confirmed hypoglycemic episodes was 86% higher (p < 0.0001) whereas the rate of nocturnal hypoglycemia was 75% lower (p < 0.0001) for IDegAsp versus IGlar.Nocturnal-confirmed hypoglycemia was higher with IGlar whereas overall and diurnal hypoglycemia were higher with IDegAsp dosed at breakfast. These results highlight the importance of administration of IDegAsp with the main meal of the day, tailored to the individual patient's needs.ClinicalTrials.gov: NCT01045707 [core]) and NCT01169766 [ext]. |
url |
http://europepmc.org/articles/PMC5070831?pdf=render |
work_keys_str_mv |
AT ajaykumar efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial AT edwardfranek efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial AT jonathanwise efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial AT marcusniemeyer efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial AT henriettemersebach efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial AT rafaelsimo efficacyandsafetyofoncedailyinsulindegludecinsulinaspartversusinsulinglargineu100for52weeksininsulinnaivepatientswithtype2diabetesarandomizedcontrolledtrial |
_version_ |
1725024731212546048 |